Early generation TAVI devices | Newer generation TAVI devices | P value | |
n=391 | n=391 | ||
Age (years) | 82.29±5.67 | 82.67±6.35 | 0.377 |
Female gender, n(%) | 207 (52.9) | 208 (53.2) | 1.000 |
Body mass index (kg/m2) | 26.26±4.94 | 26.45±5.23 | 0.614 |
Risk assessment | |||
STS score | 5.04±2.83 | 5.09±2.80 | 0.792 |
Logistic EuroSCORE | 18.02±11.15 | 18.08±13.23 | 0.945 |
Cardiac risk factors | |||
Diabetes mellitus, n (%) | 82 (21.0) | 108 (27.6) | 0.037 |
Hypertension, n (%) | 323 (82.6) | 327 (83.6) | 0.775 |
Dyslipidemia, n (%) | 233 (59.6) | 255 (65.2) | 0.121 |
Clinical features | |||
Renal failure (GFR <60 mL/min/1.73 m2) | 149 (38.3%) | 96 (24.7%) | <0.001 |
COPD, n (%) | 46 (11.8) | 35 (9.0) | 0.240 |
Atrial fibrillation, n (%) | 134 (34.3) | 138 (35.3) | 0.822 |
Permanent pacemaker, n (%) | 40 (10.2) | 43 (11.0) | 0.817 |
Past medical history | |||
Previous stroke or TIA, n (%) | 34 (8.7) | 44 (11.3) | 0.283 |
Carotid artery disease, n (%) | 21 (5.5) | 29 (10.6) | 0.017 |
Coronary artery disease, n (%) | 231 (59.1) | 249 (63.7) | 0.212 |
Previous myocardial infarction, n (%) | 52 (13.3) | 55 (14.1) | 0.835 |
Previous intervention, n (%) | 108 (27.6%) | 134 (34.3%) | 0.053 |
CABG | 32 (8.5%) | 41 (10.5%) | 0.390 |
PCI | 86 (22.0%) | 106 (27.2%) | 0.097 |
Peripheral vascular disease, n (%) | 39 (10.0%) | 24 (6.1%) | 0.065 |
Echocardiographic findings | |||
Mean aortic valve area (cm2) | 0.65±0.23 | 0.68±0.27 | 0.106 |
Mean aortic valve gradient (mm Hg) | 43.19±16.48 | 41.45±19.07 | 0.199 |
LVEF (%) | 55.50±14.21 | 54.18±15.50 | 0.239 |
Moderate/severe mitral regurgitation | 68 (18.9%) | 58 (15.6%) | 0.242 |
CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation; TIA, transient ischaemic attack.